PRESS RELEASE FROM NEUROPSYCHOPHARMACOLOGY (http://www.nature.com/npp)

For papers that will be published online on 19 August 2009

This press release is copyrighted to the journal *Neuropsychopharmacology*. Its use is granted only for journalists and news media receiving it directly from the Nature Publishing Group.

*** PLEASE DO NOT REDISTRIBUTE THIS DOCUMENT ***

EMBARGO:

2:30pm London time (BST) / 9:30am US Eastern time DAY 19 August 10:30pm Japanese time / 11:30pm Australian Eastern time DAY 19 August

Wire services' stories must always carry the embargo time at the head of each item, and may not be sent out more than 24 hours before that time.

Solely for the purpose of soliciting informed comment on this paper, you may show it to independent specialists - but you must ensure in advance that they understand and accept the embargo conditions.

A PDF of the paper mentioned on this release can be found in the Academic journals section of <u>http://press.nature.com</u>. Press contacts for the journals are listed at the end of this release.

Warning: This document, and the Academic Journal paper to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of *Nature*'s content may be guilty of insider trading under the US Securities Exchange Act of 1934.

PICTURES: While we are happy for images from *Neuropsychopharmacology* to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).

HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at <u>press@nature.com</u>, citing the specific example.

PLEASE CITE NEUROPSYCHOPHARMACOLOGY AND THE NEUROPSYCHOPHARMACOLOGY WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO <u>www.nature.com/npp/</u>

Stress may increase teen risk for smoking

DOI: 10.1038/npp.2009.112

Neurobiological factors and stressful life events can trigger and prolong smoking habits in adolescents, especially in individuals with depression. The preliminary findings, reported online in this week's *Neuropsychopharmacology*, may lead to better interventions for depression and smoking in adolescents.

Most smoking habits in adults are initiated during adolescence, though the triggers that lead to such early habits are unknown. Previous studies had shown that external stress and

neurobiological factors, individually, are linked to smoking. Furthermore, it has been documented that there is a link between depression and increased risk for smoking.

In this integrated study, Uma Rao and colleagues looked at the role of neurobiological factors and external stress, such as family and peer relationships, on smoking behavior in adolescents. The scientists followed 151 adolescents for up to five years to monitor their life events, brain stress levels, depressive episodes, and smoking habits. Brain stress levels were measured by recording individuals' cortisol levels – a stress hormone that is normally released as a coping mechanism in response to stressful situations.

Rao and colleagues found that adolescents who had high cortisol levels were more likely to begin smoking, and that stressful experiences further increased this risk. The high cortisol levels and stressful experiences in adolescents accounted for some of this association between depression and smoking, but the authors caution that these findings need to be verified with a larger study.

Author contact:

Uma Rao, MD (UT Southwestern Medical Center, Dallas, TX, USA) Tel: +1 214 648 5288; E-mail: uma.rao@utsouthwestern.edu

Editorial contact:

Diane Drexler (Neuropsychopharmacology, Nashville, TN, USA) Tel: +1 615 324 2371; E-mail: journal@acnp.org

PRESS CONTACTS

For media inquiries relating to embargo policy for the Journal Neuropsychopharmacology:

Neda Afsarmanesh (Nature New York) Tel: +1 212 726 9231; E-mail: <u>n.afsarmanesh@us.nature.com</u>

Ruth Francis (*Nature* London) Tel: +44 20 7843 4562; E-mail: <u>r.francis@nature.com</u>

For media inquiries relating to the American College of Neuropsychopharmacology: Tel: +1 615 324 2360; E-mail: acnp@acnp.org

About Nature Publishing Group (NPG)

Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.

Focusing on the needs of scientists, *Nature* (founded in 1869) is the leading weekly, international scientific journal. In addition, for this audience, NPG publishes a range of *Nature* research journals and *Nature Reviews* journals, plus a range of prestigious academic journals including society-owned publications. Online, nature.com provides over 5 million visitors per month with access to NPG publications and online databases and services, including *Nature News* and *NatureJobs* plus access to *Nature Network* and Nature Education's Scitable.com.

Scientific American is at the heart of NPG's newly-formed consumer media division, meeting the needs of the general public. Founded in 1845, *Scientific American* is the oldest continuously published magazine in the US and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 15 local language editions around the world it reaches over 3 million consumers and scientists. Other titles include *Scientific American Mind* and *Spektrum der Wissenschaft* in Germany.

Throughout all its businesses NPG is dedicated to serving the scientific and medical communities and the wider scientifically interested general public. Part of Macmillan Publishers Limited, NPG is a global company with principal offices in London, New York and Tokyo, and offices in cities worldwide including Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Barcelona, Munich, Heidelberg, Basingstoke, Melbourne, Paris, San Francisco, Seoul and Washington DC. For more information, please go to www.nature.com.